120 Participants Needed

His-Bundle vs Biventricular Pacing for Heart Failure

(HIS-CRT Trial)

Recruiting at 2 trial locations
AC
MB
Overseen ByMary Brown
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Rochester
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, it mentions that participants should be on optimal medical therapy for heart failure according to current guidelines, which suggests you may need to continue your existing heart failure medications.

What data supports the effectiveness of the treatment His-Bundle vs Biventricular Pacing for Heart Failure?

Research suggests that His-bundle pacing (His-CRT) may offer better heart synchronization compared to traditional biventricular pacing (BiV-CRT), as it mimics the heart's natural electrical pathways more closely, potentially benefiting patients who do not respond to BiV-CRT.12345

Is His-bundle pacing safe compared to biventricular pacing for heart failure?

The research does not provide specific safety data for His-bundle pacing compared to biventricular pacing, but both methods are used for cardiac resynchronization therapy, which is generally considered safe for treating heart failure.12367

How does His-bundle pacing differ from biventricular pacing for heart failure treatment?

His-bundle pacing is unique because it aims to achieve more natural heart activation by directly stimulating the His bundle, which can lead to more physiologic heart contractions compared to traditional biventricular pacing that uses leads in both ventricles.12348

Research Team

Roderick Tung, MD | The University of ...

Roderick Tung, MD

Principal Investigator

University of Arizona

VK

Valentina Kutyifa, MD, PhD

Principal Investigator

University of Rochester

Eligibility Criteria

This trial is for heart failure patients with right bundle branch block who meet specific criteria: they have certain levels of heart function and symptoms, are at least 18 years old, and follow optimal medical therapy. It's not for those with left bundle branch block, other ECG issues, or a life expectancy under one year.

Inclusion Criteria

My heart function is severely reduced, and I have a specific heart rhythm pattern.
I am receiving the best current treatment for heart failure.
I am 18 years old or older.
See 3 more

Exclusion Criteria

I am willing and able to follow the study's requirements.
You are not expected to live for more than 12 months.
Pregnancy or planned pregnancy during duration of the study
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) or cardiac resynchronization therapy (BIV-CRT)

6 months

Follow-up

Participants are monitored for changes in left ventricular ejection fraction, ECG biomarkers, NT-proBNP levels, and echocardiography biomarkers

18 months

Treatment Details

Interventions

  • BIV-CRT
  • His-CRT
Trial OverviewThe study compares two types of pacemaker implantations in heart failure patients: His-bundle pacing (His-CRT) versus traditional cardiac resynchronization therapy (BIV-CRT). The goal is to see which method works better for correcting the heartbeat.
Participant Groups
2Treatment groups
Active Control
Group I: BIV-CRT implantationActive Control1 Intervention
BIV-CRT implantation includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
Group II: His-CRT implantationActive Control1 Intervention
His-CRT implantation includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular lead, and an endocardial His-bundle pacing leads directly pacing the intrinsic conduction system.

BIV-CRT is already approved in European Union, United States for the following indications:

🇪🇺
Approved in European Union as Biventricular Pacing for:
  • Heart failure with reduced ejection fraction (LVEF ≤35%) and left bundle branch block (LBBB)
  • Heart failure with reduced ejection fraction (LVEF ≤35%) and wide QRS
🇺🇸
Approved in United States as Biventricular Pacing for:
  • Heart failure with reduced ejection fraction (LVEF ≤35%) and left bundle branch block (LBBB)
  • Heart failure with reduced ejection fraction (LVEF ≤35%) and wide QRS

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Rochester

Lead Sponsor

Trials
883
Recruited
555,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+

Findings from Research

In a study involving patients with heart failure and left bundle branch block, both His-bundle pacing and conventional biventricular pacing significantly reduced mechanical dyssynchrony after 6 months, with no significant differences between the two methods.
Both pacing techniques also improved global longitudinal strain, indicating enhanced heart function, but again, there were no significant differences in the improvements between the His-CRT and BiV-CRT groups.
Efficacy on resynchronization and longitudinal contractile function comparing His-bundle pacing to conventional biventricular pacing. - A substudy to the His-alternative study.Højgaard, EV., Philbert, BT., Linde, JJ., et al.[2023]
In the His-SYNC pilot trial involving 41 patients, His bundle pacing (His-CRT) showed significantly greater QRS narrowing compared to biventricular pacing (BiV-CRT), indicating better electrical resynchronization.
Although there was a trend towards higher echocardiographic response rates in the His-CRT group, no significant differences in cardiovascular hospitalization or mortality were found, suggesting that while His-CRT may improve electrical function, its impact on clinical outcomes needs further investigation.
On-treatment comparison between corrective His bundle pacing and biventricular pacing for cardiac resynchronization: A secondary analysis of the His-SYNC Pilot Trial.Upadhyay, GA., Vijayaraman, P., Nayak, HM., et al.[2020]
His-bundle pacing (HBP) is a feasible alternative to biventricular pacing (BiVP) for cardiac resynchronization therapy (CRT), showing equivalent clinical responses in patients with heart failure after 1 year of follow-up.
In a study of 29 patients, 72% showed electrical resynchronization with HBP, indicating that this method may be effective for a broader range of patients with left bundle branch block than previously thought.
His-bundle pacing versus biventricular pacing in cardiac resynchronization therapy patients: A crossover design comparison.Lustgarten, DL., Crespo, EM., Arkhipova-Jenkins, I., et al.[2016]

References

Efficacy on resynchronization and longitudinal contractile function comparing His-bundle pacing to conventional biventricular pacing. - A substudy to the His-alternative study. [2023]
On-treatment comparison between corrective His bundle pacing and biventricular pacing for cardiac resynchronization: A secondary analysis of the His-SYNC Pilot Trial. [2020]
His-bundle pacing versus biventricular pacing in cardiac resynchronization therapy patients: A crossover design comparison. [2016]
Upgrade of cardiac resynchronization therapy by utilizing additional His-bundle pacing in patients with inotrope-dependent end-stage heart failure: a case series. [2022]
Effectiveness of conduction system pacing for cardiac resynchronization therapy: A systematic review and network meta-analysis. [2023]
A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. [2016]
His Resynchronization Versus Biventricular Pacing in Patients With Heart Failure and Left Bundle Branch Block. [2021]
His-bundle pacing versus cardiac resynchronisation therapy: Effect on ECG parameters of repolarization. [2022]